Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012 Jun 28; 366(26):2443-54
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, ..., Kollia GD, Gupta A, Wigginton JM, Sznol M. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. N Engl J Med. 2012 Jun 28; 366(26):2443-54
This article is an interesting phase I trial of a novel T-cell modulating antibody, anti-programmed-death 1 (anti-PD-1). The study gives interesting results (responses and disease stabilization) in patients with various primaries.
The PD-1 inhibitory receptor is expressed by T cells during long-term antigen exposure and results...
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.